SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of experimental cancer drug begins
Disease control TerminatedThis early-stage study tested a new cancer drug called PF-07820435, both alone and combined with an existing immunotherapy drug (sasanlimab), in people with advanced solid tumors. The main goals were to find safe doses and look for early signs that the treatment might help shrink…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
Major trial halted: did new drug boost cancer survival?
Disease control TerminatedThis large study aimed to see if adding an experimental drug called Xevinapant to standard chemoradiation treatment could better control locally advanced head and neck cancer and help patients live longer without the cancer returning. It involved 730 adults with newly diagnosed, …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First patients test new cancer drug in early safety trial
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early trial halted: testing a powerful combo for tough head & neck cancers
Disease control TerminatedThis early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation for patients with advanced head and neck cancer. It focused on measuring side effects, especially in the mouth and skin, to see if the …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC